ROCKVILLE, Md., April 30,
2024 /PRNewswire/ -- I-Mab (the "Company")
(NASDAQ: IMAB), a U.S.-based, global biotech company,
exclusively focused on the development and potential
commercialization of highly differentiated immunotherapies for the
treatment of cancer, today announced that it has filed its annual
report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and
Exchange Commission ("SEC") on April 30,
2024.
The annual report is available on the Company's investor
relations website at ir.i-mabbiopharma.com and on
the SEC's website at www.sec.gov. The Company
will provide hard copies of the annual report, free of charge, to
its shareholders and ADS holders upon written request. Requests
should be directed to Investor Relations, I-Mab, 2440 Research
Blvd., Suite 400, Rockville, MD,
20850.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company,
exclusively focused on the development and potential
commercialization of highly differentiated immunotherapies for the
treatment of cancer. I-Mab has established operations in the U.S.
in Rockville, Maryland, and in
San Diego, California. For more
information, please visit http://www.i-mabbiopharma.com and follow
us on LinkedIn and X.
I-Mab Contacts
Investors &
Media
|
Tyler Ehler
|
Senior Director,
Investor Relations
|
IR@i-mabbiopharma.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/i-mab-filed-2023-annual-report-on-form-20-f-302130508.html
SOURCE I-Mab Biopharma